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Insulin receptor substrate-1MicroRNAs (miRNAs) play an important role in insulin signaling and insulin secretion, but the role
of miRNAs in the association between obesity and hepatic insulin resistance is largely unknown.
This study reports that saturated fatty acid (SFA) and high fat diet (HFD) signiﬁcantly induce
miR-195 expression in hepatocytes, and that the insulin receptor (INSR), not insulin receptor
substrate-1 (IRS-1), is a direct target of miR-195. Furthermore, the ectopic expression of miR-195
suppresses the expression of INSR, thereby impairing the insulin signaling cascade and glycogen
synthesis in HepG2 cells. These ﬁndings suggest that the dysregulation of miR-195 by SFA is a
detrimental factor for hepatic insulin sensitivity.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Obesity is a rapidly increasing global health problem that is clo-
sely linked to the pathogenesis of insulin resistance [1]. Insulin
resistance is deﬁned as an inadequate response of the peripheral
tissues to insulin, and is a hallmark of type 2 diabetes mellitus
(T2DM) and metabolic syndrome [2,3]. The ectopic accumulation
of fatty acids in the liver, termed hepatic steatosis, results in a dys-
regulation of the cellular metabolism and can speciﬁcally provoke
insulin resistance in hepatocytes [1,4]. Several lines of evidence
have been suggested to elucidate the implications of excess satu-
rated fatty acids (SFA) on hepatic insulin resistance, such as the
accumulation of diacylglycerol (DAG) and ceramide, oxidative
stress, mitochondrial dysfunction, etc. [4,5]. Despite these ﬁndings,
the precise mechanisms through which elevated SFA results in
hepatic insulin resistance are unclear.
The liver plays a critical role for carbohydrate homeostasis that
regulates the balance between the glycogen metabolism andgluconeogenesis, according to the metabolic demands [2,4]. In this
process, insulin signaling is one of the most important regulatory
mechanisms, which is initiated by insulin binding to insulin
receptor (INSR). This ligand-receptor interaction induces tyrosine
phosphorylation of insulin receptor substrate-1 (IRS-1), subse-
quently transmitting the signals from IRS-1 to down-stream
enzymes, such as PI3K, PDK-1 and Akt2 [6]. On the other hand,
an overload of SFA, such as palmitate, increases the intermediate
lipid metabolites including ceramide and DAG, which leads to
insulin resistance resulting from the serine phosphorylation of
IRS-1 via protein kinase C, JNK, and IKK [1,7]. Although inappropri-
ate post-translational modiﬁcation and down-regulation of IRS-1
by SFA have detrimental effects on insulin sensitivity, several
studies have suggested that the down-regulation of INSR also con-
tributes to the pathogenesis of insulin resistance and T2DM [8–11].
Mice lacking the INSR gene suffer from the rapid onset of hypergly-
cemia and hyperinsulinemia, followed by diabetic ketoacidosis and
early postnatal death [12]. The conditional knockouts of INSR in
the liver result in the development of hyperglycemia, hyperlipid-
emia, hyperinsulinemia, and obesity [13]. A large number of stud-
ies already have revealed a modest decrease in INSR in T2DM
patients [10,11]. These ﬁndings support the central role of hepatic
INSR in the whole body insulin sensitivity. On the other hand, the
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Fig. 1. SFA palmitate-induced insulin resistance and up-regulation of miR-195 in HepG2 cells. (A) HepG2 cells were preincubated with or without palmitate (0.5 mM) for
18 h. The cells were serum-starved for 4 h and then, incubated in the presence or absence of insulin (100 nM) for 30 min. The expression (INSR, IRS-1 and Akt2) and
phosphorylation (pINSR, pIRS-1 and pAkt2) of insulin signaling intermediates were analyzed by immunoblot. The immunoblot is representative of ﬁve independent
experiments. (B–D) The immunoblot intensities were quantiﬁed by densitometry, and were normalized to the amount of b-actin. Blot intensities are expressed as the relative
ratio, where the intensity of the control (open column) was set to one. (E) The expression of miR-195 was quantiﬁed by qRT-PCR from control and palmitate-treated (0.5 mM,
18 h) HepG2 cells. The values are expressed as the relative ratio, where the intensity of the control (open column) was set to one. Values are means ± S.E.M. from at least three
independent experiments; ⁄⁄P < 0.01; ⁄⁄⁄P < 0.001.
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tion of INSR is largely unknown.
MicroRNAs (miRNAs) are a family of 19–25-nucleotide, highly
conserved, endogenous non-coding RNAs that modulate target
gene expression at the post-transcriptional level [14]. Their biolog-
ical function is known to suppress gene expression mainly by base-
pairing to the 30 untranslated regions (30UTRs) of the target mRNAs,
eventually triggering either degradation of the target mRNAs or the
suppression of translation [14]. A growing body of evidence
suggests that miRNAs regulate a range of gene functions in both
normal and pathological states, and the aberrant expression of
miRNAs are involved in the development of many diseases, such
as proliferative, neurodegenerative and metabolic diseases
[14,15]. Since the ﬁrst discovery that miRNA is actively involved
in metabolic regulation, such as amino acid catabolism [16], a
number of studies have suggested that miRNAs play signiﬁcant
roles in both glucose homeostasis and lipid metabolism implicated
in insulin resistance and T2DM [17,18]. Previous studies have
shown that the insulin resistance induced by a high fat diet
(HFD) up-regulates certain miRNAs, such as miR-96, miR-126,
and miR-195, in the liver, and that miR-96 and miR-126 impair
hepatic insulin signaling and the glucose metabolism by suppress-
ing IRS-1 expression [18,19]. Although the aberrant expression of
miR-195 is involved in a range of diseases, such as cancer, cardiac
hypertrophy and heart failure [20], the implication of miR-195 in
hepatic insulin sensitivity is lacking. The present study found thatSFA and HFD up-regulates miR-195 expression in hepatocytes. In
addition, this study showed, for the ﬁrst time, that miR-195
suppresses the expression of INSR via an direct binding site in its
30UTR, causing impaired insulin signaling and glycogen metabo-
lism. Therefore, miR-195 is causally linked to the development of
insulin resistance by SFA.
2. Materials and methods
2.1. Cell culture, palmitate treatment, and transfection of miRNA
mimics
HepG2 cells (ATCC, #77400) derived from human liver
carcinoma were cultured in MEM alpha containing 10% FBS and
1% penicillin–streptomycin. For palmitate-induced insulin
resistance, the cells were treated with BSA-conjugated palmitate
(0.5 mM) for 18 h [21]. For insulin stimulation, the cells were
serum-starved for 4 h, and then stimulated with insulin (100 nM,
Sigma) for 30 min [22]. For miRNA mimics or plasmids transfec-
tion, HepG2 cells were reverse-transfected using G-fectin (Genolu-
tion, Korea) according to the manufacturer’s instructions.
2.2. Animal and HFD-induced insulin resistance
All animal procedures were performed in accordance with the
rules of the Animal Use and Care Committee at Dongguk
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Fig. 2. HFD-induced insulin resistance and up-regulation of miR-195 in DIO mice. Mice were fed either NFD or HFD for 14 weeks. HFD developed impaired glucose tolerance
and hyperglycemia, as shown in Suppl. 2. (A–D) Mice fed NFD (open column) and HFD (closed column) were fasted overnight and sacriﬁced 20 min after i.p. injections of
vehicle or insulin (2U/kg body weight). Representative immunoblots (2 from 10 mice/group) obtained from liver lysates were shown in A. The expression (INSR, IRS-1 and
Akt2) and phosphorylation (pINSR, pIRS-1 and pAkt2) of insulin signaling intermediates in the liver were analyzed by densitometry, and were normalized to the amount of b-
actin. The values are expressed as the relative ratio, where the intensity of the control (open column) was set to one. (E) The expression of miR-195 were quantiﬁed by qRT-
PCR frommice fed NFD (open column) and HFD (closed column). The values are expressed as the relative ratio, where the intensity of NFDmice (open column) was set to one.
Values are means ± S.E.M. from at least six individuals; ⁄P < 0.05; ⁄⁄P < 0.01.
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mal, Inc (Seoul, Korea). The mice were kept in a temperature-
controlled facility with a 12:12 h light–dark cycle and given access
to food and water ad libitum. At 6 weeks of age, the mice were fed
either a normal fat diet (NFD, 11% calories from fat) or a HFD (60%
calories from fat; Dyets Inc., Bethlehem, PA) for 14 weeks. The body
weight was measured every week. At the end of experiment, the
mice were fasted overnight and subjected to an oral glucose toler-
ance test (OGTT) and biochemical analysis, as described previously
[21].
2.3. RNA preparation and quantitative real-time RT-PCR (qRT-PCR)
The total cellular RNAs were isolated using a miRNeasy Mini Kit
(Qiagen). For qRT-PCR, cDNA was synthesized using M-MLV
reverse transcriptase (Promega) and ampliﬁed with oligo dT (Bion-
ics, Seoul, Korea), as described elsewhere [19]. To measure the
expression levels of miRNAs, the cDNAs were synthesized using a
miScript reverse transcription Kit (Qiagen) and subjected to qRT-
PCR using a miScript SYBR Green PCR Kit (Qiagen) in
Light-Cycler™480 (Roche-Applied Science, Mannheim, Germany).
The U6 snRNAs was used as the internal control.
2.4. Dual luciferase reporter assay
To generate the reporter gene constructs, human INSR (387nt)
or IRS-1 (110nt) 30UTR containing either the wild-type miR-195
binding sites (INSR 3Uwt or IRS-1 3Uwt) or the mutated miR-195
binding site (INSR 3Umut) was cloned into the pmirGLO Dual-luciferase miRNA target expression vector (Promega). The lucifer-
ase assays were performed using a Dual luciferase reporter system
(Promega) according to the manufacturer’s instructions. Brieﬂy, L6
GLUT4myc cells were cotransfected in 12-well plates with miR-
195 mimic or scrambled control miRNA mimic (scRNA) and
pmirGLO vectors containing the empty, wild-type or mutant
30UTRs. After 24 h, the cells were lysed using a passive lysis buffer.
The Fireﬂy and Renilla luciferase activities were measured on a Sir-
ius L (Titertek-Berthold, Germany). The relative luciferase activity
was calculated by normalizing the ratio of Fireﬂy/Renilla luciferase
to that of the scRNA-transfected cells.
2.5. Glycogen assay
HepG2 cells were reverse-transfected with miR-195 mimic or
scRNA. After 48 h, the cell culture medium was changed to MEM
alpha without FBS for 4 h, and then incubated with DMEM contain-
ing high glucose levels in the absence or presence of insulin
(100 nM) for 90 min. After washing three times with ice-cold
PBS, the glycogen contents of the cells were measured using a
Glycogen colorimetry assay Kit II (Biovision) according to the
manufacturer’s instructions.
2.6. Antibodies and immunoblotting
The antibody against IRS-1 was purchased from Upstate (Lake
Placid, NY). The antibody against phospho-IRS-1 and b-actin was
supplied by Santa Cruz Biotechnology (Santa Cruz, CA). All other
antibodies were obtained from Cell Signaling Technology (Beverly,
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Fig. 3. Targeting sites of miR-195 in the 30UTRs of INSR and IRS-1, and an
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sequence of miR-195 was predicted to target INSR and IRS-1 30UTRs. (B) For the Dual
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was cotransfected with either scRNA control (open column) or designated miR-195
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as the means ± S.E.M. from three independent experiments. ⁄⁄⁄P < 0.001.
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elsewhere [19]. The proteins were visualized using ECL Western
Blotting Detection Reagents (GE Healthcare, UK). The immunoblot
intensities were quantiﬁed by densitometry using an analytical
scanning system (Alpha Imager HP, Alpha Innotech).
2.7. Database and statistical analysis
The targeting sites on INSR or IRS-1 30UTR of miRNAs were ana-
lyzed using a TargetScan (http://www.targetscan.org/index.html)
and PicTar (http://www.pictar.org). The values are expressed as
the means ± S.E.M. from at least three independent experiments.
Where applicable, the signiﬁcance of the difference was analyzed
using a Student’s t test for unpaired data.
3. Results
3.1. SFA impairs insulin signaling and induces miR-195 expression
To examine the effect of SFA on insulin signaling in hepatocytes,
HepG2 cells were treated with palmitate (0.5 mM for 18 h), whichis the most abundant SFA in the blood. Palmitate treatment
reduced the protein expression of INSR and IRS-1 in HepG2 cells
considerably (Fig. 1A–C) compared to the vehicle-treated control,
whereas the expression of Akt2 and b-actin were unaffected
(Fig. 1A and D). Moreover, palmitate inhibited signiﬁcantly the
insulin-stimulated phosphorylation of INSR concomitant with the
insulin signaling intermediates, such as IRS-1 and its downstream
molecule, Akt2 in HepG2 cells (Fig. 1A–D). These results show that
SFA palmitate impairs insulin signaling in HepG2 cells by reducing
INSR and IRS-1 expression. According to previous reports, the
expression of miR-195 is increased signiﬁcantly in the liver of a
T2DM animal [23] and in the plasma from T2DM patients [24].
As palmitate reduced the expression of INSR and IRS-1 in HepG2
cells, the expression of miR-195, which presumably target both
INSR and IRS-1 30UTR, was next analyzed. Consistent with previous
studies, palmitate increased the expression of miR-195
signiﬁcantly in HepG2 cells (Fig. 1E) in a dose- and time-dependent
manner (Suppl. 1A–D), suggesting that miR-195 may be involved
in the reduction of INSR and IRS-1, as well as in impaired insulin
signaling by SFA.
3.2. Expression of miR-195 is increased in the liver of diet-induced
obesity (DIO) mice
DIO was reported to impair insulin signaling in hepatocytes and
myocytes [1]. Therefore, we examined how HFD affects the expres-
sion of miR-195 and how this contributes to the development of
insulin resistance. In the present study, HFD (60% kcal from fat
for 14 weeks) in mice increased the body weight, fasting blood
glucose signiﬁcantly (Suppl. 2A), and impaired the whole-body dis-
posal of blood glucose (Suppl. 2B) compared to the normal fat diet
(NFD), clearly showing that DIO mice developed hyperglycemia
and insulin resistance. Moreover, the protein expression levels of
INSR and IRS-1 were reduced drastically in the liver of DIO mice,
whereas Akt2 and b-actin were unaffected (Fig. 2A–D). The insu-
lin-stimulated phosphorylation of INSR and insulin signaling inter-
mediates was also analyzed in the liver of DIO mice. As expected,
HFD reduced signiﬁcantly the insulin-stimulated phosphorylation
of INSR, IRS-1, and Akt2, resulting mainly from the reduced expres-
sion of INSR and IRS-1 (Fig. 2A–D). The miR-195 level in insulin-
responsive tissues, such as liver and skeletal muscle, from DIO
mice was next analyzed. Interestingly, the miR-195 level was up-
regulated signiﬁcantly in the liver of DIO mice, but not in the skel-
etal muscle (Fig. 2E). These ﬁndings suggest that HFD increases the
miR-195 expression in hepatocytes with a concomitant decrease in
INSR and IRS-1 protein expression, suggesting that miR-195 may
participate in the development of hepatic insulin resistance in
DIO mice.
3.3. INSR gene is a direct target of miR-195
Based on in silico analysis using TargetScan and PicTar, the
30UTRs of the INSR and IRS-1 genes contain the predicted conserved
binding sites for miR-195. Because miR-195 expression in hepato-
cytes was up-regulated by SFA and HFD, an increase in miR-195
may be involved in the reduction of INSR and IRS-1 by SFA. There-
fore, Dual luciferase reporter assay was performed to determine if
miR-195 promotes INSR and/or IRS-1 down-regulation by directly
targeting their 30UTRs. Alignment analysis showed that human
INSR 30UTR contains a putative conserved binding site for miR-
195 (Fig. 3A). Luciferase constructs containing a putative binding
site of miR-195 identiﬁed in INSR 30UTR (wild-type; INSR 3Uwt),
or mutated nucleotides of the same (INSR 3Umut) in pmirGLO vec-
tor were developed (Fig. 3B). Reporter constructs, which included a
ﬁreﬂy luciferase cassette to allow normalization of the internal
Renilla luciferase activity, were cotransfected transiently together
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transfection of miR-195 mimic in the presence of the INSR 3Uwt
construct resulted in a signiﬁcant decrease in luciferase activity
compared to its mutant counterpart INSR 3Umut (Fig. 3C). This
shows that miR-195 targets INSR 30UTR directly and represses INSR
expression at the translational level. Next, a highly conserved puta-
tive binding region within the 30UTR of human IRS-1 gene for miR-
195 (Fig. 3A) was cloned into the pmirGLO vector (wild-type; IRS-1
3Uwt) (Fig. 3B), and subjected to Dual luciferase reporter assay. The
luciferase activity of IRS-1 3Uwt was not reduced signiﬁcantly by
miR-195 mimic, compared to scRNA control (Fig. 3C). This suggests
that miR-195 does not target IRS-1 30UTR directly and is not
involved in the repression of IRS-1 expression at the translational
level.
3.4. Expression of INSR is repressed by miR-195 at the post-
transcriptional level
Because INSR was revealed as a direct target of miR-195, the
ectopic expression of miR-195 should reduce the expression of
INSR, leading to insulin resistance in hepatocytes. To examine this
further, HepG2 cells were reverse-transfected with miR-195 mimic
using G-fectin. Measurement of the transfected miRNA by qRT-PCR
indicated that miR-195 was increased by >2000-fold, to a level
vastly greater than the endogenous miR-195 (Suppl. 3). Therefore,
all miRNAs were transfected at the concentration of 200 nM with
same transfection condition, and then, the expressions of mRNA
and protein levels of INSR and insulin signaling intermediates were
analyzed. The ectopic expression of miR-195 showed a signiﬁcantdecrease in INSR mRNA, concomitant with the substantial suppres-
sion in INSR protein, compared to scRNA control (Fig. 4A and B). On
the other hand, the ectopic expression of miR-195 did not affect
the mRNA and protein levels of insulin signaling intermediates,
such as IRS-1, Akt2 and GSK3b in HepG2 cells (Fig. 4A and B). More-
over, the transfection of 20-O-methyl-modiﬁed antisense oligonu-
cleotide against miR-195 (antimiR-195) in hepatocytes increased
INSR expression signiﬁcantly compared with scRNA control, and
completely abolished miR-195-induced INSR suppression
(Fig. 4B). These results suggest that miR-195 down-regulates the
mRNA and protein expression of INSR without apparently
changing IRS-1 expression in HepG2 cells. To further conﬁrm INSR
regulation by miR-195 in palmitate-treated HepG2 cells, antimiR-
195 was transfected and incubated in the presence or absence of
palmitate (Fig. 4C). AntimiR-195 partially but signiﬁcantly rescued
palmitate-induced INSR suppression in HepG2 cells, indicating that
up-regulation of miR-195 contributes to palmitate-induced INSR
suppression in hepatocytes.
3.5. Ectopic expression of miR-195 impairs insulin signaling and
glycogen metabolism
As miR-195 reduces the mRNA and protein of INSR, the ectopic
expression of miR-195 might be causally linked to impaired insulin
signaling and glycogen metabolism in HepG2 cells. To determine if
miR-195 is involved in the development of insulin resistance, we
analyzed the insulin-stimulated phosphorylation of insulin
signaling intermediates and glycogen synthesis in the presence
or absence of the ectopic expression of miR-195 in HepG2 cells.
A 
β-Actin 
Akt2
pAkt2
pIRS-1 
IRS-1 
GSK3β
pGSK3β
Insulin - - + + 
scRNA - - + + 
miR-195 - - + + 
 B
lo
t i
nt
en
si
ty
 
(R
el
at
iv
e 
ra
tio
)
B 
pINSRINSR
***
Insulin
- - + + 
scRNA - - + + 
miR-195
- - + + 
C 
***
 B
lo
t i
nt
en
si
ty
 
(R
el
at
iv
e 
ra
tio
)
INSR
IRS-1 pIRS-1 
 B
lo
t i
nt
en
si
ty
 
(R
el
at
iv
e 
ra
tio
)
***
***
pAkt2 pGSK3β
pINSR
**
G
ly
co
ge
n
(R
el
at
iv
e 
ra
tio
)
**
Insulin
- - + + 
scRNA - - + + 
miR-195
- - + + 
- - + + 
scRNA - - + + 
miR-195
Insulin - - + + 
scRNA - - + + 
miR-195 - - + + 
D E 
Insulin + + + + 
Fig. 5. Impaired insulin signaling and insulin-stimulated glycogen synthesis by the ectopic expression of miR-195. HepG2 cells were transfected with scRNA control or miR-
195 mimic. After 48 h of transfection, the cells were incubated in the presence or absence of insulin (100 nM) for 30 min, and were subjected to immunoblotting. (A) The
protein expression (INSR, IRS-1, Akt2, and GSK3b) and phosphorylation (pINSR, pIRS-1, pAkt2, and pGSK3b) levels of the insulin signaling intermediates were analyzed by
immunoblotting. The immunoblot is representative of ﬁve independent experiments. (B–D) The immunoblot intensities were quantiﬁed by densitometry, and were
normalized to the amount of b-actin. Blot intensities are expressed as the relative ratio, where the intensity of the control (open column) was set to one. (E) The glycogen
contents were quantiﬁed in the presence (closed column) or absence (open column) of insulin (100 nM) from scRNA control and miR-195 mimic-transfected HepG2 cells. The
values are expressed as the relative ratio, where the intensity of the normal control was set to one. Values are means ± S.E.M. from at least four independent experiments;
⁄⁄⁄P < 0.001.
3944 W.-M. Yang et al. / FEBS Letters 588 (2014) 3939–3946The expression of INSR was reduced signiﬁcantly (60%) by the
ectopic expression of miR-195, whereas the expression of IRS-1,
Akt2 and GSK3b were unaffected compared to scRNA control
(Fig. 5A–C). The ectopic expression of miR-195 also reduced signif-
icantly the insulin-stimulated phosphorylation of INSR and its
downstream molecules, IRS-1, Akt2 and GSK3b, in HepG2 cells
(Fig. 5A–D). This was attributed mainly to the reduced expression
of INSR. In addition, this study examined how miR-195 affects the
insulin-stimulated glycogen synthesis in the presence or absence
of insulin (Fig. 5E). In the control, insulin increased the cellular gly-
cogen content signiﬁcantly, whereas insulin-stimulated glycogene-
sis was barely observed after the ectopic expression of miR-195 in
HepG2 cells. Therefore, the ectopic expression of miR-195 impairs
insulin signaling and insulin-stimulated glycogen metabolism in
HepG2 cells through the repression of INSR expression.
4. Discussion
The key ﬁndings of this study were that miR-195 is up-regu-
lated by SFA, leading to impaired insulin signaling and glycogen
metabolism through the suppression of INSR in HepG2 cells. The
cellular treatment of SFA palmitate resulted in a signiﬁcant
increase in miR-195 (Fig. 1), and miR-195 decreased INSR expres-
sion directly through post-transcriptional suppression (Figs. 3 and
4), resulting in insulin resistance in HepG2 cells (Fig. 5). Moreover,
miR-195 was up-regulated in the liver of DIO mice (Fig. 2). There-fore, these ﬁndings reveal a novel mechanism whereby the induc-
tion of miR-195 by SFA is involved in the development of hepatic
insulin resistance.
Hsa-miR-195 is an intronic miRNA of a hypothetical protein,
LOC284112, which is located on chromosome, 17p13.1 [25]. Based
on the expression proﬁling and target validation studies by ectopic
expression, the aberrant expression of miR-195 has been reported
to be associated with multiple diseases, such as cancer, cardiac
hypertrophy, and heart failure [20]. Recently, miR-195 was
reported to be the ﬁrst miRNA that targets GLUT3, and is involved
in the glucose metabolism of bladder cancer cells [26]. In the
present study, the treatment of SFA palmitate up-regulated the
expression of miR-195 in HepG2 cells. Similarly, the expression
of miR-195 was also induced by palmitate in cardiomyocytes, lead-
ing to apoptosis through the down-regulation of Sirt1 and Bcl-2
[27]. Interestingly, we also found that the expression of miR-195
was increased signiﬁcantly in the liver of the DIO mice, suggesting
that the up-regulation of miR-195 may be actively involved in the
development of insulin resistance and T2DM. These ﬁndings are
consistent with previous studies. Based on global miRNA expres-
sion analysis, the expression of miR-195 is increased signiﬁcantly
in the liver of a Goto-Kakizaki rat, a T2DM animal model [23].
The miR-195 level is signiﬁcantly increased in the retina of diabetic
rats, leading to diabetic retinopathy complications [28]. Further-
more, Karolina, et al. recently found that the miR-195 level in
plasma is correlated positively with the body mass index (BMI)
W.-M. Yang et al. / FEBS Letters 588 (2014) 3939–3946 3945and blood pressure [29], and cross-sectional studies revealed a
drastic increase in the miR-195 level in the plasma from T2DM
patients [24]. Therefore, miR-195 might be one of the components
in SFA-induced lipotoxicity in the cells. Hence, the induction of
miR-195 in the liver appears to be a risk factor for insulin resis-
tance and T2DM. Moreover, miR-195 may be used as a biomarker
for diagnostic and therapeutic purposes because it is readily
detectable in the circulatory blood. Further study is clearly
warranted.
To the best of the authors’ knowledge, there is no evidence
demonstrating the mechanism through which excess SFA up-
regulates the expression of miR-195. In silico analysis, however,
suggests that several transcription factors, such as SREBPs,
PPARs, CEBPA, and p53, may bind to speciﬁc sites on the miR-
195 gene promoter regions. Because the activation of SREBPs
are known to be essential for diabetic hepatic steatosis and car-
bohydrate-induced hypertriglyceridemia [30], the miR-195 level
in the liver may be up-regulated by SFA or HFD through SREBPs
activation. PPARs are also well-known transcription factors
activated by HFD, and are strongly implicated in T2DM and
metabolic syndrome [31]. Another adipogenic transcription
factor, CEBPA is activated by high energy nutrients [32].
Furthermore, the levels of CEBPA and p53 expression are up-
regulated in DIO mice [32,33]. Although further study will be
needed, the up-regulation of miR-195 in hepatocytes might be
triggered through the activation of certain transcription factors
regulated by SFA or DIO.
This study showed that the ectopic expression of miR-195
suppresses the mRNA and protein of INSR, but not IRS-1, in
hepatocytes (Fig. 4). In addition, the ectopic accumulation of
SFA causes a substantial decrease in IRS-1 and INSR expression,
both at the transcriptional and post-transcriptional levels [1,7].
In this process, SFA reduces the IRS-1 level transcriptionally
and post-transcriptionally [1,7]. Although in silico analysis sug-
gested IRS-1 to be a target of miR-195, the results from the Dual
luciferase assay and ectopic expression clearly suggest that IRS-1
is not a direct target gene of miR-195 in human hepatocytes.
Therefore, miR-195 is considered a causative component in INSR
suppression in hepatocytes, except for IRS-1, at the post-tran-
scriptional level. Recently, Mortuza et al. reported that miR-195
expression was up-regulated in the retinas of diabetic rats,
leading to down-regulation of Sirt1 [34]. Sirt1 is a protein deace-
tylase that has been implicated in the regulation of metabolic
activity, and its expression is decreased in insulin resistance, oxi-
dative stress, and inﬂammation [35]. If Sirt1, in consort with
AMPK, is a component of the adaptive response against insulin
resistance and a dysregulation of the metabolic activity, miR-
195 may aggravate insulin resistance, T2DM, and metabolic
syndrome.
In conclusion, miR-195 is induced by SFA palmitate, and sup-
presses INSR, but not IRS-1, by targeting INSR 30UTR directly.
The expression of miR-195 is also up-regulated substantially in
the liver of DIO mice. The ectopic expression of miR-195 results
in a drastic repression of INSR protein expression, and eventually
causes impaired insulin signaling and glycogen synthesis in
HepG2 cells. Overall, these results clearly suggest that miR-195
is causally involved in the development of insulin resistance
induced by SFA.Acknowledgement
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